Table 4 Antithrombotic therapy in patients with and without care coordination during the campaign period

Antithrombotic therapy

11 (84.6)

59 (76.6)

 Oral anticoagulant agents

9 (69.2)

53 (68.8)

  Warfarin

1 (11.1)

10 (18.9)

  DOACs

8 (88.9)

43 (81.1)

 Antiplatelet agents

2 (15.4)

8 (10.4)

CHADS₂ score low (score: 0)

N = 0

N = 6

 Oral anticoagulant agents

0 (0.0)

2 (33.3)

  Warfarin

0 (0.0)

0 (0.0)

  DOACs

0 (0.0)

2 (100.0)

CHADS₂ score intermediate (score: 1)

N = 3

N = 7

 Oral anticoagulant agents

2 (66.7)

7 (100.0)

  Warfarin

0 (0.0)

3 (42.9)

  DOACs

2 (100.0)

4 (57.1)

CHADS₂ score high (score: ≥2)

N = 10

N = 64

 Oral anticoagulant agents

7 (70.0)

44 (68.8)

  Warfarin

1 (14.3)

7 (15.9)

  DOACs

6 (85.7)

37 (84.1)

OAC therapy based on JCS 2013 guidelines

9 (69.2)

55 (71.4)